Par Pharmaceuticals

Subscribe to Par Pharmaceuticals

pills-tablets.jpgIPNews® – The Federal Circuit on Friday affirmed a Texas federal court’s patent infringement finding and accompanying injunction barring three generic drug manufacturers from making, selling or marketing generic versions of Pozen Inc.’s migraine treatment Treximet.

Par Pharmaceutical Inc., Alphapharm Pty Ltd. and Dr. Reddy’s Laboratories Inc. could not overcome the presumption of validity of…

pills-tablets.jpgIPNews® – The Federal Circuit on Tuesday partially reversed a lower court’s finding that a number of Santarus Inc.’s patent claims for its heartburn drug Zegerid are invalid, giving Santarus another crack at hanging Par Pharmaceuticals Inc. out to dry for trying to market a generic version of the drug.

The district court slipped up…